| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-10-12 | evacetrapib | patients with high-risk atherosclerotic cardiovascular disease | 3 | Eli Lilly (USA - IN) | Cardiovascular diseases |
| 2015-10-12 | Viaskin® | Crohn's disease | DBV Technologies (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases | |
| 2015-10-12 | romosozumab (CDP7851/AMG 785) | postmenopausal women with low bone mineral density | 2 | Amgen (USA - CA) UCB (Belgium) | Bone diseases - Women's health |
| 2015-10-10 | ceftazidime/avibactam (CAZ-AVI) | complicated urinary tract infections (cUTI) | Allergan (Ireland) | Infectious diseases | |
| 2015-10-10 | Cosentyx® - secukinumab (AIN457) | psoriasis | 3 | Novartis (Switzerland) | Autoimmune diseases - Dermatological diseases |
| 2015-10-10 | VX-440 | cystic fibrosis | 1 | Vertex Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2015-10-10 | VX-152 | cystic fibrosis | Vertex Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases | |
| 2015-10-09 | delafloxacin | acute bacterial skin and skin structure infections (ABSSSI) | 3 | Melinta Therapeutics (USA - CT) | Infectious diseases |
| 2015-10-09 | Ad26.ZEBOV and MVA-BN-Filo | Ebola fever | 3 | Crucell Holland, a J&J company (USA - NJ) | Infectious diseases |
| 2015-10-09 | Trumenba® - rLP2086 coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines | 2 | Pfizer (USA - NY) | Infectious diseases | |
| 2015-10-09 | GLPG1837 | cystic fibrosis | 1 | Abbvie (USA - IL) Galapagos (Belgium) | Rare diseases - Genetic diseases |
| 2015-10-09 | KUR-211 | tibial plateau fractures that require fixation and grafting | 2b | KUROS Biosurgery (Switzerland) | Bone diseases |
| 2015-10-08 | BI 655066 | moderate-to-severe plaque psoriasis | 2 | Boehringer Ingelheim (Germany) | Autoimmune diseases - Dermatological diseases |
| 2015-10-08 | Gilenya® (fingolimod) | relapsing forms of multiple sclerosis | 3 | Novartis (Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
| 2015-10-08 | Lemtrada® (alemtuzumab) | multiple sclerosis | 3 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2015-10-08 | SAR428926 | advanced solid tumors | 1 | Sanofi | Cancer - Oncology |
| 2015-10-07 | C1 derived vaccine | preclinical | Dyadic (USA - FL) Sanofi Pasteur (France) | Infectious diseases - Veterinary medicine | |
| 2015-10-07 | Aubagio® (teriflunomide) | relapsing multiple sclerosis (RMS) | 3 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2015-10-06 | BioChaperone Lispro® U100 | patients with type 1 diabetes using insulin pump therapy | 1b | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-10-06 | RVT-101 | Alzheimer\'s disease | 3 | Axovant Sciences (Bermuda - USA - NY) | Neurodegenerative diseases |
